Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Amylin Bows Out Gracefully
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Chris,

Good post.Type I's will also need a basal injection or two a day but most Type II's will only need Afrezza.

1) Critics of inhaled insulin say, even with Afrezza, people with Diabetes still have to take injections. Is Mannkind planning to come up with basal inhaled insulin using the Technosphere particle in near future?
Mr. Mann: AFREZZATM addresses prandial (mealtime) glucose. But glucose is supplied by the liver between meals so in type 1 and late stage type 2 a person also needs a basal insulin. Basal insulin today requires one or two injections daily. However, for the 70% of type 2 diabetics who have not progressed to basal/bolus therapy. AFREZZA alone without basal injections has provided excellent control in a recent trial.

MannKind has been exploring various technologies to provide better basal insulins. We cannot yet speak about these.

http://afresa.blogspot.com/2010/06/interview-with-alfred-mann-ceo-of.html


"Aren’t most Type 2s currently treated with a basal insulin only, instead of mealtime dosing?

Al:Yes, but that’s the wrong way around. The correct therapy should be a good prandial insulin and not long-term insulin — Afresa in particular because it turns off glucose production and delivery from the liver. Our latest trials of 600 patients are showing even more significant benefits from the product than our original trials; the most recent trial appears to show that this should replace frontline treatment for all Type 2 patients."

http://www.diabetesmine.com/2009/11/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann.html

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply